Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE®) in the Treatment of Patients with Heart Failure with Preserved Ejection Fraction in France, Based on the EMPEROR-Preserved Clinical Trial

Laurent Fauchier (), Nicolas Lamblin, Jean Tardu, Lucile Bellier, Harinala Groyer, Deborah Ittah, Julien Chollet, Stephan Linden and Pierre Lévy
Additional contact information
Laurent Fauchier: CHRU Tours - Centre Hospitalier Régional Universitaire de Tours, EES - Éducation Éthique Santé EA 7505 - UT - Université de Tours
Nicolas Lamblin: CHRU Lille - Centre Hospitalier Régional Universitaire [CHU Lille]
Jean Tardu: Creativ-Ceutical France - Creativ-Ceutical
Lucile Bellier: Laboratoire d'Ethique Médicale, de Droit de la Santé et de Santé Publique - UPD5 - Université Paris Descartes - Paris 5
Harinala Groyer: Boehringer Ingelheim
Deborah Ittah: Boehringer Ingelheim
Julien Chollet: Boehringer Ingelheim Pharma GmbH & Co. KG
Stephan Linden: Boehringer Ingelheim
Pierre Lévy: LEDa - Laboratoire d'Economie de Dauphine - IRD - Institut de Recherche pour le Développement - Université Paris Dauphine-PSL - PSL - Université Paris Sciences et Lettres - CNRS - Centre National de la Recherche Scientifique, Legos - Laboratoire d'Economie et de Gestion des Organisations de Santé - Université Paris Dauphine-PSL - PSL - Université Paris Sciences et Lettres

Post-Print from HAL

Abstract: Introduction: The efficacy and safety of empagliflozin in the treatment of heart failure with preserved ejection fraction (HFpEF) were demonstrated in the EMPEROR-Preserved trial, which showed a 21% reduction in combined risks of cardiovascular death or HF hospitalization [hazard ratio (HR) 0.79; 95% confidence interval (CI) 0.69–0.90, p

Keywords: public health; heart failure; Clinical trial (search for similar items in EconPapers)
Date: 2023
New Economics Papers: this item is included in nep-eur
Note: View the original document on HAL open archive server: https://hal.science/hal-04439876v2
References: View complete reference list from CitEc
Citations:

Published in PharmacoEconomics - Open, 2023, 8, pp.19-30. ⟨10.1007/s41669-023-00432-z⟩

Downloads: (external link)
https://hal.science/hal-04439876v2/document (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:hal-04439876

DOI: 10.1007/s41669-023-00432-z

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().